ArticleAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2010
Dense deposit disease associated with monoclonal gammopathy of undetermined significance.
Article in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
56 citing papers in PubMed, 1 synthesis or guideline pooled it, 120 citations in OpenAlex.
- The evaluation of monoclonal gammopathy of renal significance: a consensus report of the International Kidney and Monoclonal Gammopathy Research Group.Nature reviews. Nephrology · 2019Guideline
- C3 glomerulopathy in transplant "like yet unlike native": Pathophysiology, recent advances in therapeutics and evolving paradigms.World journal of transplantation · 2026Review
- Review
- Clinical and Histologic Predictors of Kidney Outcomes in C3 Glomerulopathy and Idiopathic Membranoproliferative GN.Clinical journal of the American Society of Nephrology : CJASN · 2025Article
- Challenges in the Diagnosis and Management of Immune Complex-Mediated Membranoproliferative Glomerulonephritis and Complement 3 Glomerulopathy.Kidney international reports · 2025Review
- The role of complement in kidney disease.Nature reviews. Nephrology · 2023Review
- Article
- C3 glomerulonephritis associated with monoclonal gammopathy: a retrospective case series study from a single institute in China.Renal failure · 2021Article
- Treatment of Monoclonal Gammopathy-associated C3 Glomerulopathy With Daratumumab-based Therapy.Clinical lymphoma, myeloma & leukemia · 2021Article
- The Clone Wars: Diagnosing and Treating Dysproteinemic Kidney Disease in the Modern Era.Journal of clinical medicine · 2021Review
- Poor allograft outcome in Indian patients with post-transplant C3 glomerulopathy.Clinical kidney journal · 2021Article
- Monoclonal Gammopathy of Undetermined Significance (MGUS)-Not So Asymptomatic after All.Cancers · 2020Review
- Outcome of C3 glomerulopathy patients: largest single-centre experience from South Asia.Journal of nephrology · 2020Article
- A Narrative Review on C3 Glomerulopathy: A Rare Renal Disease.International journal of molecular sciences · 2020Review
- Factor H Autoantibodies and Complement-Mediated Diseases.Frontiers in immunology · 2020Article
- Monoclonal immunoglobulin mediates complement activation in monoclonal gammopathy associated-C3 glomerulonephritis.BMC nephrology · 2019Article
- Pathophysiology and management of monoclonal gammopathy of renal significance.Blood advances · 2019Review
- Successful Renal Outcome in Membranoproliferative Glomerulonephritis Following Treatment of the Underlying Subtle Clone: A Case Report.Mayo Clinic proceedings. Innovations, quality & outcomes · 2018Article
- Dominant C3 glomerulopathy: new roles for an old actor in renal pathology.Journal of nephrology · 2018Review
- C3 Glomerulopathy: Ten Years' Experience at Mayo Clinic.Mayo Clinic proceedings · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Dense deposit disease (DDD) is a rare glomerular disease that typically affects children, young adults, and much less commonly, older patients. The pathophysiologic process underlying DDD is uncontrolled activation of the alternative pathway (AP) of complement cascade, most frequently secondary to an autoantibody to C3 convertase called C3 nephritic factor, although mutations in factor H and autoantibodies to this protein can impair its function and also cause DDD. Since 1995, we have diagnosed DDD in 14 patients aged 49 years or older; 10 of these patients (71.4%) carry a concomitant diagnosis of monoclonal gammopathy of undetermined significance (MGUS). In 1 of these 10 patients, the index case described here, we evaluated the AP and showed low serum AP protein levels consistent with complement activity, heterozygosity for the H402 allele of factor H, and low levels of factor H autoantibodies, which can affect the ability of factor H to regulate AP activity. In aggregate, these findings suggest that in some adults with MGUS, DDD may develop as a result of autoantibodies to factor H (or other complement proteins) that on a permissive genetic background (the H402 allele of factor H) lead to dysregulation of the AP with subsequent glomerular damage. Thus, DDD in some older patients may be a distinct clinicopathologic entity that represents an uncommon complication of MGUS.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.